Study Evaluating Clinical Trial Bias in Pharma Presents Encouraging Evidence
The study, which evaluated the top 20 pharmaceutical companies, identified Amgen, AstraZeneca, and Celgene as the most dedicated to clinical trial data sharing.
GNS Healthcare Appoints AJPB Editor Jan Berger, MD, to Board
GNS Healthcare, a leading provider of big data analytics in health care, today announced the appointment of Jan Berger, MD, MJ, to its board of directors. Berger, who served CVS Caremark as chief clinical officer for nearly 10 years, is an internationally recognized expert in medication adherence and value-based health care. She is currently president and CEO of Health Intelligence Partners, a consultancy providing business strategies and solutions to clients across the care continuum.
NanoString Announces New PanCancer Immune Panel
The panel, developed in collaboration with immunooncology scientists around the world, including at INSERM, will help researchers create a profile of the human immune response in all cancer types.
Addressing Health Technology Barriers for Baby Boomers
Although baby boomers are expected to place a large burden on healthcare resources, consumer health technologies could help stem increasing needs and costs, according to a new study in the Journal of Medical Internet Research.
Extended Use of Xtandi in Chemothrerapy-Naïve Prostate Cancer Patients
The FDA approval will greatly influence the reach of the drug which was approved for use in advanced prostate cancer patients.
US Hospital Administrative Costs Exceed Comparable Countries
An analysis of hospital administrative costs across 8 countries found hospital bureaucracy accounts for a quarter of hospital spending in the United States.
Grant Rewards Insights Into State Healthcare Reform Implementation
The Health Care Cost Institute and the National Academy for State Healthy Policy are launching a grant program to fund studies that will analyze how the states are implementing health reform.
ONC Revises 2014 EHR Certification
The Office of the National Coordinator for Health IT released a final rule for electronic health record certification that offers more flexibility for health information technology developers, providers, and consumers.
Watchful Waiting in Prostate Cancer: Role of Ethnicity
The retrospective study, conducted at the Thomas Jefferson University in Philadelphia, found that watchful waiting among black men with early stage prostate cancer who had undergone surgery, resulted in a more aggressive disease.
Young Adult ED Use Decreased Under ACA Provision
Extending young adults’ eligibility for health insurance on their parents’ plans under an Affordable Care Act provision led to a decrease in emergency department visits.
AACR's Policy Statement Urges FDA-Regulation of Laboratory-Developed Tests
The statement points to the increased complexity of some of the LDTs and highlights patient safety issues that are at stake.
Premiums for ACA Insurance Plans Will Decline Slightly in 2015
In the largest cities in 15 states plus the District of Columbia the average insurance premiums for the second-lowest-cost silver plan will decline by 0.8% in 2015, according to an analysis from the Kaiser Family Foundation.
HHS Will Award $60 Million in Grants to Marketplace Navigators
The Department of Health and Human Services (HHS) announced it will award $60 million in Navigator grants to 90 organizations in states with federally facilitated and state partnership marketplaces.
DEA Moves to Curtail Drug Abuse
With the objective of reducing drug abuse, especially by teenagers, the D.E.A. will now allow patients and their relatives to mail-in their unneeded stockpiles of prescription drugs back to the pharmacies.
Global Study Identifies Prediabetes as a Risk Factor for Cancer
A meta-analysis comprising 16 studies and 891,426 participants from various regions of the world shows that prediabetes increases the risk of cancer by 15%, with differing risks depending on the type of cancer.
Androgen-Deprivation is Essential in Prostate Cancer Regimen
A joint statement by ASCO and CCO published new guidelines in the treatment of metastatic CRPC.
NICE Rejects Abraxane for Pancreatic Cancer
NICE does not deem Abraxane more effective than FOLFIRINOX, in addition to the fact that it causes severe side effects.
Superbugs an Increasing Problem in Hospitals
For patients who develop infections while staying in a hospital, the chances of it becoming drug resistant increases 1% for each day of hospitalization, according to researchers from the Medical University of South Carolina (MUSC).
Genomic Analysis Determines Post-Surgery Treatment in Prostate Cancer
The results of the genomic data can guide treatment decisions post-surgery in prostate cancer.
Hospitals, Providers Continue to Struggle with Stage 2 Meaningful Use
Numbers for Stage 2 meaningful use attestation remain very low, according to the latest numbers from the Centers for Medicare and Medicaid Services.
Massachusetts’ Foray Into Narrow Networks Shows Potential
The narrow health insurance networks that have become more common under the Affordable Care Act can reduce patient spending by as much as a third, according to research from MIT.
Bristol-Myers Sues Merck Over US Immunotherapy Patent
“Merck is threatening to exploit that invention,” known as immunotherapy, with a later-developed method of treatment, in violation of a May 20 patent, Bristol-Myers said in a lawsuit filed yesterday in federal court in Wilmington, Delaware. The New York-based company is seeking unspecified damages.
Companies Race To Adjust Health-Care Benefits As Affordable Care Act Takes Hold
Large businesses expect to pay between 4 and 5 percent more for health-care benefits for their employees in 2015 after making adjustments to their plans, according to employer surveys conducted this summer.
Highmark Takes on Outpatient Markups
Highmark, an insurer with its own health system, is challenging a growing and controversial billing practice that also happens to be a central part of some health system integration strategies.
New State Law on Generic Pricing Upsets PBMs
The law could restrict the use of less-expensive generics with the availability of newer, more-expensive drugs.